Latest Tax Rebates News

Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.

AnteoTech Ltd reports a strong FY2025 with doubled sales revenue, strategic partnerships, and key product milestones in battery materials and life sciences diagnostics.

Biotron Limited reported a significantly reduced net loss of $318,572 for FY2025, bolstered by a $1.27 million capital raise and a $1.81 million R&D tax rebate, as it advances clinical and preclinical antiviral programs.

BluGlass Limited reported a 16% rise in revenue to $11.7 million for FY25, driven by key US Department of Defense contracts and new partnerships. However, the company’s net loss increased 8% to nearly $11 million amid ongoing R&D investment and operational scaling.

AnteoTech Ltd reported a 110% revenue increase to A$968,878 in FY2025 alongside a 24% reduction in net loss, driven by strategic cost savings and key partnerships. Leadership renewal and product validation position the company for growth in battery and life sciences markets.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.

AnteoTech Ltd has received a $2.59 million cash rebate from the Australian Tax Office for its 2025 R&D activities, underscoring the success of its recent strategic initiatives.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.